The Depo-Provera cancer lawsuit is one of the fastest growing mass torts in the country right now. Thousands of women claim this popular birth control shot caused brain tumors called meningiomas, and they want Pfizer to pay for the damage.
If you received Depo-Provera injections and later developed a brain tumor, you may qualify to file a claim. The litigation has picked up serious momentum heading into 2026.
Lawsuits are now consolidated in a federal MDL in Alabama. Bellwether trials could begin as early as late 2026, which means settlement talks may not be far behind.
This article covers everything you need to know. You’ll find the latest case updates, estimated payouts, eligibility rules, filing deadlines, and a step by step breakdown of how to join the litigation. One study found that women who used Depo-Provera for over a year faced a 5.6 times higher risk of developing meningioma compared to women who never used it.
What Is the Depo-Provera Cancer Lawsuit About
The Depo-Provera cancer lawsuit alleges that Pfizer’s injectable contraceptive causes meningioma brain tumors and that the company failed to warn patients about this risk. Women across the United States are filing claims arguing they were never told their birth control shots could lead to brain tumors requiring surgery.
Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin. It’s been on the market since 1992. Millions of women have received it as a quarterly injection to prevent pregnancy.
The core allegation is simple: Pfizer knew or should have known about the meningioma risk and said nothing. Internal documents and published research dating back years suggest the company had access to safety data it chose not to share with patients or doctors.
These cases are product liability claims based on a failure to warn theory. That means plaintiffs don’t have to prove the drug was defective in how it was manufactured. They have to show the company didn’t provide adequate warnings about known dangers.
| Key Facts | Details |
|---|---|
| Drug Name | Depo-Provera (medroxyprogesterone acetate) |
| Manufacturer | Pfizer (originally Pharmacia & Upjohn) |
| Primary Allegation | Failure to warn about meningioma risk |
| Injury Claimed | Meningioma brain tumors |
| Legal Theory | Product liability, failure to warn |
| Year Approved by FDA | 1992 |
The first wave of lawsuits began filing in late 2024. By early 2025, hundreds had been consolidated into a single federal proceeding. The number of cases continues to climb every month.
Depo-Provera Lawsuit Update for 2026
As of 2026, the Depo-Provera litigation is in the discovery and bellwether preparation phase within the federal MDL. The case count has surpassed expectations, and attorneys on both sides are exchanging documents and deposing key witnesses.
Judge Abdul K. Kallon in the Northern District of Alabama is overseeing MDL No. 3127. He has set a structured schedule for the litigation that includes fact sheet submissions, expert discovery, and the selection of bellwether cases.
Bellwether trials are test cases. The court picks a small number of representative lawsuits, tries them before a jury, and uses the results to guide settlement negotiations for the rest. Think of them as dress rehearsals for the larger litigation.
Here’s where the timeline stands heading into 2026:
| Milestone | Expected Timing |
|---|---|
| Plaintiff Fact Sheets Due | Completed / Ongoing |
| Expert Discovery Phase | Early to Mid 2026 |
| Bellwether Case Selection | Mid 2026 |
| First Bellwether Trial | Late 2026 or Early 2027 |
| Settlement Talks | Potentially Late 2026 Onward |
New cases are still being filed every week. Attorneys report that the total case count in the MDL has grown past 2,000 claims and continues to rise. The litigation is gaining momentum, not losing it.
Pfizer has not yet made any public settlement offers. The company is expected to defend aggressively through the bellwether phase before considering global resolution.
Depo-Provera Lawsuit Settlement Amounts
No settlements have been finalized in the Depo-Provera litigation as of early 2026. However, legal analysts and mass tort attorneys have published estimated ranges based on the severity of injuries and comparable pharmaceutical cases.
Settlement predictions vary widely depending on the strength of each individual case. The biggest factors include how long the plaintiff used Depo-Provera, the size and location of their tumor, and whether surgery was required.
Attorneys handling these cases have suggested three general tiers:
| Settlement Tier | Estimated Range | Criteria |
|---|---|---|
| Tier 1 (Severe) | $300,000 to $1,500,000+ | Large tumor, craniotomy surgery, lasting neurological damage |
| Tier 2 (Moderate) | $100,000 to $300,000 | Diagnosed meningioma, treatment required, partial recovery |
| Tier 3 (Lower) | $30,000 to $100,000 | Smaller tumor, monitoring only, no surgery needed |
These numbers are projections, not guarantees. Every case is different. A woman who underwent multiple brain surgeries will likely receive far more than someone whose tumor was found early and monitored without intervention.
For comparison, the Zantac cancer lawsuits saw individual settlement values ranging from tens of thousands to over a million depending on injury severity. Mass tort payouts in pharmaceutical cases tend to follow this tiered structure.
The actual settlement values will become clearer once bellwether trials produce verdicts. A large plaintiff verdict could push Pfizer toward higher settlement offers. A defense win could reduce the overall payout pool.
Key Takeaway: The Depo-Provera cancer lawsuit targets Pfizer for failing to warn about brain tumor risks, and while no settlements have been paid yet, estimated payouts range from $30,000 to over $1.5 million per person depending on injury severity.
Depo-Provera Brain Tumor Lawsuit Explained
The Depo-Provera brain tumor lawsuit centers on a specific type of tumor called a meningioma. These tumors grow in the meninges, the protective membranes surrounding the brain and spinal cord.
Meningiomas are technically classified as benign in most cases. But “benign” is misleading here. A tumor pressing against your brain can cause seizures, vision loss, headaches, memory problems, and personality changes.
Many women in this lawsuit needed craniotomy surgery to remove their tumors. That’s a procedure where surgeons open the skull. Recovery takes months. Some women suffered permanent neurological damage.
The key symptoms that led to diagnosis for many plaintiffs include:
- Chronic, worsening headaches
- Vision changes or partial blindness
- Seizures with no prior history
- Memory loss or cognitive decline
- Weakness or numbness on one side of the body
- Personality changes noticed by family members
Removing a meningioma doesn’t always solve the problem. These tumors have a recurrence rate. Some women have undergone two or three surgeries. Others live with ongoing neurological deficits that prevent them from working or caring for their families.
The emotional toll is enormous too. Many plaintiffs describe feeling betrayed. They trusted a routine birth control shot and ended up in brain surgery. That sense of broken trust is part of what’s driving this litigation forward.
Depo-Provera Meningioma Lawsuit Details
The Depo-Provera meningioma lawsuit specifically targets the connection between long-term progestin exposure and the growth of meningioma tumors. Meningiomas express progesterone receptors, which means they can be fueled by hormones like those found in Depo-Provera.
This isn’t just a theory. Published medical research supports the connection. A landmark French study conducted by ANSM (the French National Agency for the Safety of Medicines) analyzed data from over 18,000 women. It found a clear dose-response relationship.
Women who used injectable medroxyprogesterone acetate for more than one year had a dramatically higher risk of meningioma compared to non-users. The longer the use, the higher the risk.
| Duration of Use | Increased Meningioma Risk |
|---|---|
| Less than 1 year | Minimal increase |
| 1 to 3 years | Roughly 3 times higher |
| 3 to 5 years | Approximately 4.5 times higher |
| More than 5 years | 5.6 times higher |
Other progestin-containing drugs have already faced regulatory action over meningioma risks. In France, cyproterone acetate was restricted after similar findings. The Depo-Provera situation follows the same pattern.
Plaintiffs in these lawsuits typically show two things: a documented history of Depo-Provera injections and a subsequent meningioma diagnosis confirmed by MRI or surgical pathology. Medical records linking these two facts form the backbone of each case.
Who Qualifies for the Depo-Provera Lawsuit
You may qualify for the Depo-Provera lawsuit if you received Depo-Provera injections and were later diagnosed with a meningioma brain tumor. That’s the basic threshold, though certain factors make a case stronger.
The strongest claims come from women with these characteristics:
- Received multiple Depo-Provera injections over a period of one year or more
- Diagnosed with meningioma (confirmed by imaging or biopsy)
- The diagnosis came during or after the period of Depo-Provera use
- Required medical treatment such as surgery, radiation, or ongoing monitoring
- Suffered documented harm including lost wages, medical bills, or lasting health effects
You do not need to have been diagnosed with a malignant (cancerous) tumor. Meningiomas are the primary injury at issue, and most are classified as benign. The harm comes from the tumor’s location and the treatment required to address it.
Family members of women who died from meningioma complications may also be eligible to file wrongful death claims. These cases carry different procedural requirements depending on the state.
If you only received one or two injections and were never diagnosed with any tumor, you likely do not have a viable claim at this time. The litigation focuses on women who developed meningiomas, not on fear of future injury.
Depo-Provera Lawsuit Eligibility Requirements
Eligibility for the Depo-Provera lawsuit requires meeting specific criteria related to drug use, diagnosis, and timing. Attorneys evaluate each potential case against a checklist of factors before accepting representation.
Here are the core requirements most law firms are looking for:
| Requirement | Details |
|---|---|
| Drug Used | Depo-Provera or generic medroxyprogesterone acetate injection |
| Duration of Use | At least 1 year of injections (stronger cases: 2+ years) |
| Diagnosis | Meningioma confirmed by MRI, CT scan, or surgical pathology |
| Timing | Diagnosis during or within 10 years after last injection |
| Medical Records | Documented injection history and tumor diagnosis |
| Statute of Limitations | Must file within your state’s deadline (varies by state) |
Some firms will accept cases with shorter use periods if the medical evidence strongly supports causation. Every case gets reviewed individually.
You’ll need access to your medical records. This includes pharmacy records showing Depo-Provera injections and imaging or pathology reports confirming a meningioma diagnosis. If your original doctor’s office has closed, records can often be obtained through hospital systems or insurance companies.
One common question is whether women who used generic versions of the drug qualify. The answer is yes. The active ingredient, medroxyprogesterone acetate, is the same regardless of brand. Cases involving generic versions follow the same legal arguments.
Key Takeaway: You qualify for the Depo-Provera lawsuit if you received injections for at least a year and were later diagnosed with a meningioma, and you’ll need medical records showing both your injection history and your tumor diagnosis to move forward.
Depo-Provera Lawsuit Payout Per Person
The estimated Depo-Provera lawsuit payout per person ranges from $30,000 to over $1.5 million, with the exact amount depending on injury severity, medical expenses, and the impact on the plaintiff’s daily life.
No two cases will pay the same amount. Mass tort settlements almost always use a point-based system to calculate individual awards. Points are assigned based on specific factors.
Factors that increase your payout:
- Multiple surgeries (especially craniotomies)
- Permanent neurological damage such as vision loss or cognitive impairment
- Long duration of Depo-Provera use (5+ years)
- Young age at diagnosis (more years of life affected)
- Inability to work due to the injury
- Tumor recurrence after initial treatment
Factors that could lower your payout:
- Tumor was small and only required monitoring
- Full recovery with no lasting symptoms
- Short duration of drug use
- Pre-existing conditions that could explain the tumor
Think of it like car insurance claims. A fender bender doesn’t pay the same as a totaled vehicle with injuries. The worse the damage and the clearer the other driver’s fault, the bigger the check.
Mass tort payouts also depend on the total settlement fund. If Pfizer agrees to a global settlement of, say, $2 billion and 10,000 claimants qualify, the per-person average comes out differently than if 5,000 qualify. The math shifts with every new filing.
Is the Depo-Provera Lawsuit a Class Action
The Depo-Provera lawsuit is not a class action. It is a mass tort consolidated as a multidistrict litigation (MDL), which is a different legal structure with important distinctions.
In a class action, one or a few plaintiffs represent a large group. Everyone in the class gets the same outcome. The payout per person is usually small because it’s split evenly.
An MDL works differently. Each plaintiff files their own individual lawsuit. The cases are grouped together for pretrial efficiency, but each person’s claim is valued separately based on their own injuries and circumstances.
| Feature | Class Action | MDL (Mass Tort) |
|---|---|---|
| Individual claims | No, grouped as one | Yes, each case is separate |
| Payout structure | Same for everyone | Varies by injury severity |
| Average payout | Usually low ($10 to $500) | Can be $30,000 to $1,500,000+ |
| Court handling | One judge, one trial | One judge for pretrial, separate valuations |
| Plaintiff control | Limited | Each plaintiff has their own attorney |
This distinction matters a lot for potential payouts. Because your case is individually evaluated in an MDL, women with severe injuries and strong evidence can receive significantly higher compensation than those with less serious claims.
The MDL is currently housed in the U.S. District Court for the Northern District of Alabama under MDL No. 3127. Judge Abdul K. Kallon is the presiding judge. All federal Depo-Provera meningioma cases are being transferred to this court for coordinated pretrial proceedings.
The Link Between Depo-Provera and Meningioma
The link between Depo-Provera and meningioma is supported by multiple peer-reviewed studies showing that prolonged exposure to medroxyprogesterone acetate significantly increases the risk of developing these brain tumors.
Meningioma tumors contain progesterone receptors. This has been known in the medical community for decades. When a drug like Depo-Provera floods the body with synthetic progesterone, it can stimulate the growth of cells in the meninges.
The most significant evidence comes from the French ANSM study, which was published in the BMJ in 2024. This study tracked tens of thousands of women and found a dose-dependent relationship. More injections meant more risk.
Other key studies supporting the connection include:
- A 2024 BMJ analysis showing a 5.6x increased risk with prolonged use
- Earlier research on cyproterone acetate (another progestin) that led to drug restrictions in Europe
- Case reports from neurosurgeons documenting meningioma patients with Depo-Provera histories
- Pathology studies showing progesterone receptor positivity in the majority of meningioma tissue samples
The science here is strong enough that it prompted the FDA to act. In 2024, the FDA updated the Depo-Provera label to include information about the meningioma risk. That’s a meaningful regulatory move.
Pfizer is expected to challenge the causation evidence during bellwether trials. The company will likely argue that meningiomas are common and can occur without any drug exposure. Plaintiffs’ experts will counter with the statistical data showing that Depo-Provera users develop meningiomas at rates far higher than the general population.
Key Takeaway: Multiple peer-reviewed studies confirm a dose-dependent link between Depo-Provera and meningioma, with women using the drug for over five years facing 5.6 times the normal risk of developing these brain tumors.
Does Depo-Provera Increase Cancer Risk
Depo-Provera has been studied for potential cancer risk for years, and the current lawsuit focuses primarily on meningioma brain tumors, which are typically classified as benign rather than malignant (cancerous).
This is where things get confusing for a lot of people. When you search “Depo-Provera cancer lawsuit,” you’ll find results about brain tumors. That’s because in everyday language, most people use “cancer” and “tumor” interchangeably. From a legal standpoint, it doesn’t matter whether the tumor is benign or malignant. What matters is the harm it caused.
A “benign” meningioma can still:
- Require major brain surgery
- Cause permanent vision loss
- Trigger seizures and cognitive decline
- Grow back after removal
- Be fatal in rare cases
Beyond meningiomas, some earlier research has examined Depo-Provera’s relationship with breast cancer. A 2012 study published in the journal Cancer Research found a modest increase in breast cancer risk among current and recent users. However, the current wave of lawsuits is focused on meningioma, not breast cancer.
The World Health Organization classifies Depo-Provera as a Group 1 carcinogen for certain cancer types based on its hormonal composition. But the litigation playing out in 2026 is specifically about brain tumors and the failure to warn about that particular risk.
If you were diagnosed with a different type of cancer after using Depo-Provera, it’s worth discussing your situation with a mass tort attorney. The legal landscape could expand as more research comes in.
Depo-Provera Black Box Warning Explained
The Depo-Provera black box warning is the FDA’s most serious type of drug safety warning, and in 2024, the FDA updated Depo-Provera’s labeling to include information about the risk of meningioma.
A black box warning appears at the top of a drug’s prescribing information inside a bordered box. It’s reserved for the most dangerous and potentially life-threatening side effects. Depo-Provera already carried a black box warning about bone density loss. The meningioma risk information was added more recently.
Here’s why the warning matters for the lawsuit:
- It shows the FDA acknowledges the meningioma risk is real and significant
- It undermines Pfizer’s argument that the risk was unknown or speculative
- It supports plaintiffs’ claims that earlier warnings should have been issued
- It establishes a regulatory benchmark that strengthens failure-to-warn claims
| Warning Timeline | Action |
|---|---|
| 1992 | Depo-Provera approved by FDA |
| 2004 | Black box warning added for bone density loss |
| 2024 | FDA updates label to include meningioma risk information |
The timing of the 2024 update is critical. Plaintiffs argue that the scientific evidence linking Depo-Provera to meningioma was available years before the FDA acted. European regulators flagged the issue earlier. Pfizer had access to the same data.
If the company knew about the risk and delayed updating the label, that’s the foundation of a failure to warn claim. It’s like knowing the brakes on your car are faulty and not telling anyone until after the crashes start piling up.
Depo-Provera Side Effects Behind the Lawsuit
The Depo-Provera side effects at the center of this lawsuit go far beyond typical birth control complaints like weight gain or irregular bleeding. The injuries driving this litigation are serious, life-altering, and in some cases permanent.
The primary side effect fueling the lawsuit is the development of meningioma brain tumors. But many plaintiffs experienced a cascade of related health problems.
Side effects alleged in Depo-Provera lawsuits include:
- Meningioma brain tumors (the central claim)
- Chronic headaches that worsened over time
- Seizures
- Partial or complete vision loss
- Hearing changes
- Cognitive impairment and memory loss
- Personality and mood changes
- Motor skill deterioration
- Need for craniotomy brain surgery
- Tumor recurrence after surgical removal
Many women report that their symptoms developed gradually. Headaches that they blamed on stress turned out to be caused by a growing brain tumor. Vision problems they attributed to aging were actually from a meningioma pressing on the optic nerve.
The delay in recognizing symptoms is part of the tragedy. Women using Depo-Provera were never told to watch for warning signs of brain tumors. Without that information, they had no reason to suspect a connection when symptoms appeared.
Pfizer’s prescribing information mentioned common side effects like weight changes, injection site reactions, and menstrual irregularities. Meningioma was not prominently featured, if mentioned at all, for most of the drug’s time on the market.
How to File a Depo-Provera Lawsuit
To file a Depo-Provera lawsuit, you need to contact a mass tort attorney, provide your medical records, and have your case evaluated for inclusion in the MDL. The process is straightforward, and most firms handle these cases on a contingency fee basis, meaning you pay nothing upfront.
Here’s the step-by-step process:
Step 1: Gather your records. Collect medical records showing your Depo-Provera injection history and your meningioma diagnosis. Pharmacy records, insurance claims, and doctor’s notes all help.
Step 2: Contact an attorney. Reach out to a law firm that handles pharmaceutical mass tort cases. Most offer free case evaluations. You can call or submit an inquiry online.
Step 3: Case review. The attorney will review your records and determine if your case meets the eligibility criteria. This includes confirming your injection history, diagnosis, and timeline.
Step 4: Filing. If accepted, your attorney files a complaint in federal court. Your case gets transferred to MDL No. 3127 in the Northern District of Alabama.
Step 5: Participate in discovery. You may need to complete a plaintiff fact sheet, submit medical records, and possibly sit for a deposition. Your attorney guides you through each step.
| Step | What You Do | What Your Attorney Does |
|---|---|---|
| Records | Gather injection and diagnosis records | Reviews and organizes them |
| Evaluation | Share your medical history | Determines case viability |
| Filing | Sign retainer agreement | Files complaint in federal court |
| Discovery | Complete fact sheet | Handles legal filings and motions |
| Resolution | Wait for settlement or trial | Negotiates on your behalf |
You don’t have to pay anything out of pocket. Contingency fees mean the attorney only gets paid if you receive a settlement or verdict. Typical fees range from 33% to 40% of the recovery.
Key Takeaway: Filing a Depo-Provera lawsuit involves gathering your medical records, contacting a mass tort attorney for a free evaluation, and letting them handle the legal heavy lifting while you pay nothing upfront.
Depo-Provera Lawsuit Filing Deadline
The Depo-Provera lawsuit filing deadline depends on your state’s statute of limitations, which is the legal time limit for bringing a claim. Missing this deadline can permanently bar you from recovering compensation.
Statutes of limitations for personal injury and product liability cases vary from state to state. Most fall between two and six years from the date of injury or the date you discovered (or should have discovered) the connection between Depo-Provera and your tumor.
| State | Statute of Limitations | Discovery Rule |
|---|---|---|
| California | 2 years | Yes |
| Texas | 2 years | Yes |
| New York | 3 years | Yes |
| Florida | 4 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
The discovery rule is important here. Many women didn’t learn about the link between Depo-Provera and meningioma until the lawsuits made news in 2024 and 2025. Under the discovery rule, the clock starts when you knew or reasonably should have known about the connection, not when you first used the drug.
This means even if you stopped using Depo-Provera a decade ago, your claim might still be timely. The key date is when you learned that your meningioma could be connected to the drug.
Don’t assume you’ve missed the deadline. Contact an attorney and let them evaluate the timing. Many women filing in 2026 used Depo-Provera years ago but only recently learned about the lawsuit.
Depo-Provera MDL Update and Court Status
The Depo-Provera MDL (Multidistrict Litigation No. 3127) is proceeding through the pretrial phase in the Northern District of Alabama under Judge Abdul K. Kallon. As of 2026, the litigation is actively moving toward bellwether trial preparation.
An MDL consolidates all federal cases into one court for efficiency. Instead of having thousands of separate cases in dozens of different courts, everything runs through one judge. This saves time and ensures consistent rulings on shared legal questions.
Key MDL developments as of 2026:
- Case transfers are ongoing as new filings continue to pour in
- Plaintiff fact sheets are being collected and reviewed
- Document discovery from Pfizer is underway, including internal communications about the meningioma risk
- Expert witness reports are being prepared by both sides
- Bellwether case pool selection is expected by mid-2026
- Daubert hearings on expert testimony admissibility are anticipated
The Judicial Panel on Multidistrict Litigation (JPML) created this MDL in late 2024 after finding that the growing number of cases involved common questions of fact. The panel selected Alabama as the venue.
Judge Kallon has a reputation for moving cases along efficiently. His management of the pretrial schedule suggests he wants to get to bellwether trials without unnecessary delay. That’s good news for plaintiffs who don’t want to wait years for resolution.
Once bellwether trials are completed, the results will shape settlement negotiations. If juries return large verdicts for plaintiffs, Pfizer will face strong pressure to settle the remaining cases. If the defense wins, the dynamics shift.
Pfizer’s Role in the Depo-Provera Lawsuit
Pfizer is the primary defendant in the Depo-Provera lawsuit as the current manufacturer and marketer of the drug. The company acquired Depo-Provera through its merger with Pharmacia & Upjohn, which originally developed and sold the product.
Pfizer’s involvement goes beyond just putting its name on the label. Plaintiffs allege the company:
- Knew about the meningioma risk based on available scientific literature
- Failed to update the drug’s warning label to include brain tumor risks until pressured by the FDA in 2024
- Continued marketing Depo-Provera aggressively despite growing safety signals
- Did not conduct adequate post-market safety studies to evaluate the long-term tumor risk
- Profited from the drug for decades while women suffered preventable injuries
Depo-Provera has been a significant revenue generator. Millions of women in the U.S. and around the world have received the injection. At roughly $100 to $250 per injection given four times a year, the drug has brought in billions over its lifetime.
Pfizer has publicly stated that it stands behind the safety of Depo-Provera. The company is expected to argue that meningiomas are common in the general population, that the scientific evidence doesn’t prove causation, and that the drug’s labeling was adequate at all relevant times.
However, the company’s position weakened when European regulators took action before the FDA did. France flagged the meningioma risk and restricted similar progestin products. Pfizer’s argument that it didn’t know about the risk becomes harder to maintain when foreign regulators were sounding alarms publicly.
| Pfizer’s Position | Plaintiffs’ Position |
|---|---|
| Drug is safe when used as directed | Company failed to warn about known risks |
| Meningiomas are common regardless | Depo-Provera users face 5.6x higher risk |
| Labeling was adequate | Warnings were missing or inadequate for decades |
| Causation is not proven | Peer-reviewed studies support the link |
| FDA approved the product | FDA approval doesn’t shield from liability |
The outcome of this lawsuit could cost Pfizer billions. Based on the number of users, the severity of injuries, and the strength of the scientific evidence, this is one of the most significant pharmaceutical cases the company faces in 2026.
Key Takeaway: Pfizer is the primary target of this litigation, and plaintiffs argue the company knew about meningioma risks for years but chose profits over patient safety by failing to update Depo-Provera’s warning label.
Frequently Asked Questions
How much money can I get from the Depo-Provera cancer lawsuit?
Estimated payouts range from $30,000 to over $1.5 million per person.
The amount depends on the severity of your injury, whether surgery was needed, and the lasting impact on your life.
No settlements have been finalized yet, but these ranges are based on attorney projections and comparable pharmaceutical cases.
What is the deadline to file a Depo-Provera lawsuit in 2026?
The deadline depends on your state’s statute of limitations, which typically ranges from 2 to 6 years.
The clock usually starts when you discovered or should have discovered the link between Depo-Provera and your tumor.
Contact an attorney as soon as possible to make sure you don’t miss your filing window.
Does Depo-Provera actually cause brain cancer?
The lawsuit primarily involves meningioma brain tumors, which are usually benign but can still require brain surgery and cause serious harm.
Studies show a 5.6 times higher risk of meningioma with prolonged Depo-Provera use.
While meningiomas are not technically “cancer,” the injuries they cause are severe and form the basis of these legal claims.
How long does the Depo-Provera lawsuit process take?
Mass tort cases typically take 2 to 5 years from filing to resolution.
Bellwether trials are expected in late 2026 or early 2027, and settlements could follow shortly after.
Individual timelines vary, but early filers often receive payouts before later claimants.
Can I still file a Depo-Provera lawsuit if I stopped using it years ago?
Yes, you can still file even if you stopped Depo-Provera years ago.
The discovery rule in most states starts the clock when you learned about the meningioma connection, not when you last received an injection.
Many women filing in 2026 stopped using the drug five, ten, or even fifteen years ago.
The Depo-Provera cancer lawsuit is heading toward a critical phase in 2026. Bellwether trials are on the horizon. Settlement talks could follow soon after.
If you received Depo-Provera injections and developed a meningioma, now is the time to get your records together and talk to a mass tort attorney. Early filers often have an advantage in these cases.
Don’t wait for the deadline to sneak up on you. The clock is running, and the case against Pfizer is only getting stronger as more evidence comes to light.
